Literature DB >> 27011918

Hematopoietic stem cell transplantation for auto immune rheumatic diseases.

Subramanian Ramaswamy1, Sandeep Jain1, Vinod Ravindran1.   

Abstract

Stem cells have their origins in the embryo and during the process of organogenesis, these differentiate into specialized cells which mature to form tissues. In addition, stem cell are characterized by an ability to indefinitely self renew. Stem cells are broadly classified into embryonic stem cells and adult stem cells. Adult stem cells can be genetically reprogrammed to form pluripotent stem cells and exist in an embroyonic like state. In the early phase of embryogenesis, human embryonic stem cells only exist transiently. Adult stem cells are omnipresent in the body and function to regenerate during the process of apoptosis or tissue repair. Hematopoietic stem cells (HSC) are adult stem cells that form blood and immune cells. Autoimmune responses are sustained due to the perennial persistence of tissue self autoantigens and/or auto reactive lymphocytes. Immune reset is a process leading to generation of fresh self-tolerant lymphocytes after chemotherapy induced elimination of self or autoreactive lymphocytes. This forms the basis for autologous HSC transplantation (HSCT). In the beginning HSCT had been limited to refractory autoimmune rheumatic diseases (AIRD) due to concern about transplant related mortality and morbidity. However HSCT for AIRD has come a long way with better understanding of patient selection, conditioning regime and supportive care. In this narrative review we have examined the available literature regarding the HSCT use in AIRD.

Entities:  

Keywords:  European Group for Blood and Marrow Transplantation; Hematopoietic stem cell transplantation; Stem cell therapy; Systemic sclerosis; Transplant related mortality

Year:  2016        PMID: 27011918      PMCID: PMC4801796          DOI: 10.5500/wjt.v6.i1.199

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  33 in total

1.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

2.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Authors:  Pierre Quartier; Pierre Taupin; Franck Bourdeaut; Irène Lemelle; Pascal Pillet; Michel Bost; Jean Sibilia; Isabelle Koné-Paut; Sylvie Gandon-Laloum; Marc LeBideau; Brigitte Bader-Meunier; Richard Mouy; Marianne Debré; Paul Landais; Anne-Marie Prieur
Journal:  Arthritis Rheum       Date:  2003-04

Review 3.  Pathophysiology of systemic sclerosis: state of the art in 2014.

Authors:  Nicolas Dumoitier; Sébastien Lofek; Luc Mouthon
Journal:  Presse Med       Date:  2014-08-29       Impact factor: 1.228

Review 4.  One year in review 2015: systemic lupus erythematosus.

Authors:  Giulia Mirabelli; Francesca Cannarile; Cosimo Bruni; Roberta Vagelli; Rossella De Luca; Linda Carli
Journal:  Clin Exp Rheumatol       Date:  2015-06-22       Impact factor: 4.473

5.  Autologous hematopoietic stem cell transplantation for autoimmune diseases.

Authors:  A Gratwohl; J Passweg; C Bocelli-Tyndall; A Fassas; J M van Laar; D Farge; M Andolina; R Arnold; E Carreras; J Finke; I Kötter; T Kozak; I Lisukov; B Löwenberg; A Marmont; J Moore; R Saccardi; J A Snowden; F van den Hoogen; N M Wulffraat; X W Zhao; A Tyndall
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

6.  Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study.

Authors:  L R Spiegel; R Schneider; B A Lang; N Birdi; E D Silverman; R M Laxer; D Stephens; B M Feldman
Journal:  Arthritis Rheum       Date:  2000-11

7.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population.

Authors:  C Bryan; Y Howard; P Brennan; C Black; A Silman
Journal:  Br J Rheumatol       Date:  1996-11

8.  Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.

Authors:  Ola Khorshid; Chitra Hosing; Samer Bibawi; Naoto Ueno; John Reveille; Maureen D Mayes; Richard E Champlin
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

9.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

Review 10.  An update on mortality in systemic lupus erythematosus.

Authors:  A Ippolito; M Petri
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

View more
  1 in total

1.  Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study.

Authors:  Jia Zhu; Gaixiu Su; Jianming Lai; Boya Dong; Min Kang; Shengnan Li; Zhixuan Zhou; Fengqi Wu
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-20       Impact factor: 3.054

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.